Health
Dapagliflozin Misses Early Mark in COVID-19, but Kosiborod Sees Reasons for More Study – AJMC.com Managed Markets Network
The Dapagliflozin in Respiratory Failure in Patients With COVID-19 trial is the first phase 3 study to examine whether this SGLT2 inhibitor, which has proven effective…
A study that misses its mark would not typically generate this much interest, especially after trial sponsor AstraZeneca announced last month that results fell short of statistical significance. But with SGTL2 inhibitors gaining indications in heart failure and CKD, along with their original T2D approvalsconditions that put patients in danger when they get COVID-19many suspect this weekends results will not be the last word.
Since Kosiborod is one of the worlds leading experts on SGLT2 inhibitors,…
-
General11 hours agoPolice investigating after body found on road in Newborough, Gippsland
-
Noosa News22 hours agoDeaths of Karen Edwards, Tim Thomson, and Gordon Twaddle re-examined in inquest
-
Noosa News23 hours agoSecond inquest into homicide of three tourists shot dead Mount Isa in 1978 begins
-
General23 hours agoThe Church of England’s ‘turning point’ to irrelevancy